Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 12
Submit an article Journal homepage
189
Views
142
CrossRef citations to date
0
Altmetric
Review

Recent advances in therapeutic chalcones

Liming Ni AtheroGenics, Inc., 8995 Westside Pkwy, Alpharetta, GA 30004, USA. [email protected]
,
Charles Q Meng AtheroGenics, Inc., 8995 Westside Pkwy, Alpharetta, GA 30004, USA. [email protected]
&
James A Sikorski AtheroGenics, Inc., 8995 Westside Pkwy, Alpharetta, GA 30004, USA. [email protected]
Pages 1669-1691 | Published online: 25 Feb 2005

Bibliography

  • SHIMOKORIYAMA M: Ravanones, Chalcones and Aurones. Geissman TA (Ed.) The MacMillan Company, New York, (1962):286–313.
  • SCHRODER J: The chalconeistilbene-synthase type family of condensing enzymes. In: Comprehensive Natural Products Chemistry Sankawa U (Ed.) (1999):749–771
  • BOWN D: Encyclopedia of Herbs and Their Uses. Folkard C (Ed.) Dorling Kindersley Publishing, Inc., New York, (1995):238,289,329,345.
  • AL-NAKIB W, HIGGINS PG, BARROW I: Intranasal chalcone, Ro-09-0410, as prophylaxis against rhinovirus infection in human volunteers. Antimicrob . Chemother. (1988) 20(6):887–892.
  • PHILLPOTTS RJ, HIGGINS PG, WILLMAN JS: Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. Antimicrob. Chemother. (1984) 14(4):403–409.
  • CLUZAN RV, ALLIOT F, GHABBOUN S: Treament of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology (1996) 29(1):29–35.
  • BELTRAMINO R, PENENORY A, BUCETA A: An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic. Angiology (2000) 51(7)535–544.
  • WEINDORF N, SHULTZ -EHRENBURG U: Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatusand trimethylhesperidinchalcone. Z Hautkr (1987) 62(1):28–38.
  • DIMMOCK JR, ELIAS DW, KANDEPU NM: Bioactivities of chalcones. Curr. Med. Chem. (1999) 6(12):1125–1149.
  • OPLETALOVA V, SEDIVY D: Chalcones and their heterocyclic analogues as potential antifungal chemotherapeutics. Ces. Solv. Farm. (1999) 48(6):252–255.
  • OPLETALOVA V, RICICAROVA P, SEDIVY D, MELTROVA D, KRIVAKOVA J: Chalcones and their heterocyclic analogues as potential medicaments. Folia Pharm. Univ. Carol. (2000) 25:21–33.
  • OPLETALOVA V: Chalcones and their heterocyclic analogues as potential therapeutic agents for bacterial diseases. Ces. Solv. Farm. (2000) 49(6):278–284.
  • OPLETALOVA V, JAHODARL JD,24.OPLETAL L: Chalcones (1,3-diarylpropen-1-ones) and their analogues as potential therapeutic agents of diseases of the cardiovascular system. Ces. SoIv. Farm. (2003) 52(1):12–19.
  • HARAGUCHI H, ISHIKAWA H, MIZUTANI K, TAMURA Y, KINOSHITA T: Antioxidative and25.superoxide scavenging activities of retrochalcones in Clycyrrhiza inflata. Bioorg. Med. Chem. (1998) 6(3):339–347.
  • CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of26.inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol (2001) 16(8):939–946.
  • MIRANDA CL, STEVENS JF, IVANOV V et al: Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and27.flavanones in vitro. J. Agric. Food Chem. (2000) 48(9):3876–3884.
  • LEBEAU J, FURMAN C, BERNIER JL, DURIEZ P TEISSIER E, COTELLE N: Antioxidant properties of di-tert- butylhydroxylated flavonoids. Free Radic Biol.28.Med. (2000) 29(9):900–912.
  • VAYA J, BELINKY PA, AVIRAM M: Antioxidant constituents from licorice roots: isolation, structure elucidation and29.antioxidative capacity toward LDL oxidation. Free Radic Biol. Med. (1997) 23(2):302–313.
  • CIOFFI G, MORALES EL, BRACA A, DE TOMMASI N: Antioxidant chalcone glycosides and flavanones from Madura (Chlorophora) tinctoria. Nat. Prod. (2003)30.66(8):1061–1064.
  • WANG JP, TSAO LT, RAUNG SL, LIN CN: Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils. Eur. Pharmacol (1997) 320(2–3):201–208.31.
  • HSIEH HK, LEE TH, WANG JP WANG JJ, LIN CN: Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. (1998) 15(1):39–46.
  • CALLISTE C-A, LE BAIL J-C,32.TROUILLAS P et al.: Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. (2001) 21:3949–3956.
  • ZHAO F, NOZAWA H, DAIKONNYA A, KONDO K, KITANAKA S: Inhibitors of33.nitric oxide production from hops (Humulus lupulus L.). Biol. Pharm. (2003) 26(1):61–65.
  • ROJAS J, PAYA M, DEVESA I, DOMINGUEZ JN, FERRANDIZ ML: Therapeutic administration of 3,4,5-trimethoxy-4'-fluorochalcone, aselective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn-Schmiedebergs Arch. Pharmacol (2003) 368(3):225–233.
  • CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol (2001) 61(8):939–946.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129–134.
  • KO HH, TSAO LT, YU KL, LIU CT, WANG JP, LIN CN: Structure-activity relationship studies on chalcone derivatives. the potent inhibition of chemical mediators release. Bioorg. Med. Chem. (2003) 11(1):105–111.
  • HERENCIA F, LOPEZ-GARCIA MP, UBEDA A: Nitric oxide-scavenging properties of some chalcone derivatives. Nitric Oxide (2002) 6(2):242–246.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al: 4-Dimethylamino-3',4'-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects. Free Radic. Biol. Med. (2001) 30(1):43–50.
  • ROJAS J, DOMINGUEZ JN, CHARRIS JE, LOBO GM, PAYA M, FERRANDIZ ML: Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur. J. Med. Chem. (2002) 37(8):699–705.
  • ROJAS J, PAYA M, DOMINGUEZ JN, LUISA FM: The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production. Bioorg. Med. Chem. Lett. (2002) 12(15):1951–1954.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 (COX-2) in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129–134.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg. Med. Chem. Lett. (1998) 8(10):1169–1174.
  • HSIEH HK, TSAO LT, WANG JP, LIN CN: Synthesis and anti-inflammatory effect of chalcones. Pharm. Pharmacol (2000) 52 (2) :163–171.
  • BARFOD L, KEMP K, HANSEN M, KHARAZMI A: Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol (2002) 2(4):545–555.
  • DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. J. Pharm. Pharmacol (2003) 55(9):1313–1321.
  • DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: 1- (2,3,4-trimethoxypheny1)-3- (3- (2-chloroquinoliny0)-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Infiamm. Res. (2003) 52(6):246–257.
  • BALLESTEROS JF, SANZ MJ, UBEDA A et al.: Synthesis and pharmacological evaluation of 2'-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation. J. Med. Chem. (1995) 38(14):2794–2797.
  • TANAKA S, SAKATA Y, MORIMOTO K et al.: Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta Med. (2001) 67(2):108–113.
  • MADAN B, BATRA S, GHOSH B: 2'-hydroxychalcone inhibits nuclear factor-KB and blocks tumor necrosis factor-alpha- and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol Pharmacol (2000) 58(3):526–341.
  • HOWARD RB, MCDONALD AM, STEFANOPOULOS D et al: The synthetic chalcone AGI-2048 inhibits several indices of diseases in rat adjuvant arthritis. FASEB J. (2003) 17(4):A666.
  • SUNDELL CL, LANDERS UK, QIU FH et al: AGI-2048, a novel synthetic chalcone, inhibits eosinophilia, inflammatory gene expression and airway hyperresponsiveness in a murine asthma medel. Am. J. Respir. Crit. Care Med. (2003) 167:A357.
  • PETTIT GR, SINGH SB, HAMEL E, UN CM, ALBERTS DS, GARCIA-KENDALL D: Isolation and structure of the strong cell growth and tubulin inhibtor combretastatin A-4. Experientia. (1989) 45(2):209–211.
  • LIN CM, SINGH SB, CHU PS et al: Interaction of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol (1988) 34(2):200–208.
  • MOLL UM, PETRENKO 0: The MDM2-p53 interaction. Mol. Cancer Res. (2003) 1(14):1001–1008.
  • O'DWYER PJ, LACRETA F, NASH S et al.: Phase I study of thiotepa in combination with the glutathione trasferase inhibitor ethacrynic acid. Cancer Res. (1991) 51(22):6059–6065.
  • OAKLEY AJ, ROSSJOHN J, BELLO ML, CACCURI AM, FEDRICT G, PARKER MW: The three-dimensional structure of the human Pi class glutathion transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry (1996) 36(3):576–585.
  • PLOEMEN JH, BOGAARDS JJ, VELDINK GA, VAN OMMEN B, JANSEN DHM, VAN BLADEREN PJ: Isoenzyme selective irreversible inhibition of rat and human glutathione Stransferases by ethacrynic acid and two brominated derivatives. Biochem. Pharmacol (1993) 45(3):633–639.
  • STOLL R, RENNER C, HANSEN S et al.: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 40(2):336–344.
  • KUMAR SK, HAGER E, PETTI C, GURULINGAPPA H, DAVIDON NE, KHAN SR: Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. ./. Med. Chem. (2003) 46(14):2813–2815.
  • REED JC: Apoptosis-based therapies. Nat. Rev Drug Dis. (2002) 1:111–121.
  • ZHANG JY: Apoptosis-based anticancer drugs. Nature Rev. Drug Dis. (2002) 1:101–102.
  • RAFI MM, ROSEN RT, VASSIL A et al:Modulation of bc1-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. (2000) 20:2653–2658.
  • Physician's Desk Reference. (1999):3425.
  • KELLOFF GJ, LUBET RA, RL et al.: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prey (1998) 7(0:65–78.
  • TAMIR S, EIZENBERG M, SOMJEN D, IZRAEL S, VAYA J: Estrogen-like activity of glabrene and other constituents ioslated from licorice root. J. Steroid Biochem. Mol. Biol. (2001) 78:291–298.
  • YAMAZAKI S, MORITA T, ENDO H et al.: Isoligiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. (2002) 183:23–30.
  • BABA M, ASANO R, TAKAHASHI T et al.: Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. (2002) 25(2):247–250.
  • BENSON AM, HUNKELER MJ, TALALAY P: Increase of NAD(P)H: quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sri. USA (1980) 77(9):5216–5220.
  • MIRANDA CL, APONSO GL, STEVENS JF, DEINZER ML, BUHLER DR: Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells. Cancer Lett. (2000) 149:21–29.
  • DINKOVA-KOSTOVA AT, MASSIAH MA, BOZAK RE, HICKS RJ, TALALAY P: Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Li. USA (2001) 98(6):3404–3409.
  • HENDERSON MC, MIRANDA CL, STEVENS JF, DEINZER ML, BUHLER DR: LI vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica (2000) 30(3):235–251.
  • BRIDGES AJ: Chemical inhibitors of protein kinases. Chem. Rev (2001) 101(8):2541–2571.
  • YANG EB, GUO YJ, ZHANG K, CHEN YZ, MACK P: Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim. Biophys. Acta (2001) 1550:144–152.
  • NAKAMURA C, KAWASAKI N, MIYATAKA H et al.: Synthesis and biological activities of fluorinated chalcone derivatives. Bioorg. Med. Chem. (2002) 10:699–706.
  • SODERSTROM T, WADELIUS M, ANDERSSON SO et al.: 5a-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics (2002) 12(4):307–312.
  • STEERS WD: 5a-Reductase activity in theprostate. Urology (2001) 58(6.Supp1.1):17–24.
  • SHIMIZU K, KONDO R, SAKAI K, BUABARN S, DILOKKUNANANT U: A geranylated chalcone with 5a-reductase inhibitory properties from Artocarpus incisus. Phytochemistry (2000) 54:737–739.
  • DUCKI S, FORREST R, HADFIELD J et al.: Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. (1998) 8:1051–1056.
  • ROSS SA, ZAGLOUL A, NIMOF A, MEHMEDIC Z, SOHLY EN: A cytotoxic chalcone from Faramea salicifolia. Planta Med. (1999) 65(2):194.
  • DIMMOCK JR, JHA A, ZELLO GA et al.: Cytotoxic 4'-aminochalcones and related compounds. Pharmazie (2003) 58(4):227–232.
  • DIMMOCK JR, PERJESI P: Synthesis and antitumor activities of some cyclic chalcones. Cyogyszereszet (2001) 45(4):210–215.
  • HARAGUCHI H, TANIMOTO K, TAMURA Y, MIZUTAN K, KINOSHITA T: Mode of antibacterial action of retrochalcones from Cbxyrrhiza inflate. Phytochernistry(1998) 48(1):125–129.
  • KABIR AM, SHIMIZU K, AIBA Y, IGARASHI M, TAKAGI A, KOGA Y: The effect of sofalcone on indomethacin-induced gastric ulcers in a Helicobacter pylori-infected gnotobiotic murine model. Aliment Pharmacol Ther. (2000) (Suppl. 0:223–229.
  • FRITS-MOLLER A, CHEN M, FUURSTED K, CHRISTENSEN SB, KHARAZMI A: In vitro antimycobacterial and antilegionella activity of licochalcone A from Chinese licorice roots. Planta Med. (2002) 68(5):416–419.
  • ZHAI L, CHEN M, BLOM J, THEANDER TG, CHRISTENSEN SB, KHARAZMI A: The anitleishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicro. Chemother. (1999) 43:793–803.
  • KAYSER 0, KIDERLEN AF: In vitro Leishmanicidal activity of naturally occurring chalcones. Phytother: Re.s (2001) 15:148–152.
  • NIELSEN SF, CHRISTENSEN SB, CRUCIANI G, KHARAZMI A, LILJEFORS T: Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. (1998) 41(204819–4832.
  • LIU M, WILAIRAT P, GO M-L: Antimalarial alkoxylated and hydroxylated chalcones: structural-activity relationship analysis. J. Med. Chem. (2001) 44(25):4443–4452.
  • LIN Y-M, ZHOU Y, FLAVIN MT, ZHOU L-M, NIE W, CHEN F-C: Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med. Chem. (2002) 10:2795–2802.
  • ELSOHLY HN, JOSHI AS, NIMROD AC, WALKER LA, CLARK AM: Antifungal chalcones from Madura tinctoria. Planta Med. (2001) 67:87–89.
  • CHEN M, ZHAI L, CHRISTENSEN SB, THEANDER TG, KHARAZMI A: Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. (2001) 45(7):2023–2029.
  • VIANA GS, BANDEIRA MA, MATOS FJ: Analgesic and anti-inflammatory effects of chalcones isolated from Myracrodruon urundeuva allemao. Phytomedicine (2003) 10(2-3):189–195.
  • LIN CN, LEE TH, HSU ME WANG JP, KO FN, TENG CM: 2',5'-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor. J. Pharm. Pharmacol (1997) 49(5):530–536.
  • LIN CN, LU CM, LIN HC etal.: Novel antiplatelet constituents from formosan moraceous plants. J. Nat. Prod. (1996) 59(9):834–838.
  • ZWAAGSTRA ME, TIMMERMAN H, TAMURA M et al.: Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists. Med . Chem. (1997) 40(7):1075–1089.
  • KIM YP, BAN HS, LIM SS et al: Inhibition of prostalglandin E2 production by 2'-hydoxychalcone derivatives and the mechanism of action. ./. Pharm. Pharmacol (2001) 53(9):1295–1302.
  • LEE YN, YEH HI, TIAN TY, LU WW, KO YS, TSAI CH: 2',5'-Dihydroxychalcone down-regulates endothelial connexin 43 gap junctions and affects MAP kinase activation. Toxicology (2002) 179(1-2):51–60.
  • MATSUURA M, KIMURA Y, NAKATA K, BABA K, OKUDA H: Artery relaxation by chalcones isolated from the roots of Angelica keiskei. Planta Med. (2001) 76(3):230–235.
  • AIDA K, TAWATA M, SHINDO H et al: Isoliquiritigenin: a new aldose reductase inhibitor from Clycyrrhizae radix Planta Med. (1990) 56(3):254–258.
  • LIM SS, JUNG SH, JI J, SHIN KH, KEUM SR: Inhibitory effects of 2'-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation. Chem. Pharm. Bull. (2000) 48(10:1786–1789.
  • TAWATA M, AIDA K, NOGUCHI T eta/.: Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur. Pharmacol (1992) 212(1):87–92.
  • MENG CQ, ZHENG XS, NI L etal.: Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-a-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. (2004) 14:1513–1517.
  • MIDDLETON E, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implication for inflammation, heart desease, and cancer. Pharmacol Rev. (2000) 52 (4) :673–751.
  • O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47(12):2945–2964.

Websites

  • http://www.herbmed.org/herbs/herb101.htm HerbMed® — Glycyrrhiza glabra (Licorice).
  • •This website provides lists of research literatures of various medical herbs.
  • http://www.herbmed.org/herbs/herb24.htm HerbMed® — Angelica sp. (Angelica).
  • •This website provides lists of research literatures of various medical herbs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.